Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Dougados

Showing results (341-350 of 600) with videos related to

Pageof 60
Sort By:
Arthritis and Rheumatism|December 1, 2011
Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritisJérémie Sellam, Stéphanie Rouanet, Houria Hendel-Chavez, et al.
Annals of the Rheumatic Diseases|August 13, 2014
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an exampleRobert B M Landewé, Josef S Smolen, Michael E Weinblatt, et al.
Journal of Patient-Reported Outcomes|August 12, 2024
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretationDavid Cella, Christine de la Loge, Fatoumata Fofana, et al.
Arthritis and Rheumatism|July 9, 2003
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacyJacques-Eric Gottenberg, Florence Merle-Vincent, Fabrice Bentaberry, et al.
Arthritis and Rheumatism|January 13, 2011
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label studyJérémie Sellam, Houria Hendel-Chavez, Stéphanie Rouanet, et al.
Rheumatology (Oxford, England)|May 7, 2020
The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission statusCátia Duarte, Eduardo Santos, José A P da Silva, et al.
Annals of the Rheumatic Diseases|May 9, 2020
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritisAndreas Kerschbaumer, Josef S Smolen, Maxime Dougados, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisCécile Gaujoux-Viala, Josef S Smolen, Robert Landewé, et al.
The Journal of Rheumatology|March 11, 2009
Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB studyRene Westhovens, Joel M Kremer, Larry W Moreland, et al.
Clinical and Experimental Rheumatology|October 23, 2013
Fatigue in spondyloarthritis: a marker of disease activity. A cross-sectional study of 266 patientsKarine Chauffier, Simon Paternotte, Vincent Burki, et al.
Pageof 60

Showing results (341-350 of 600) with videos related to

Sort By:
Pageof 60
Arthritis and Rheumatism|December 1, 2011
Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritisJérémie Sellam, Stéphanie Rouanet, Houria Hendel-Chavez, et al.
Annals of the Rheumatic Diseases|August 13, 2014
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an exampleRobert B M Landewé, Josef S Smolen, Michael E Weinblatt, et al.
Journal of Patient-Reported Outcomes|August 12, 2024
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretationDavid Cella, Christine de la Loge, Fatoumata Fofana, et al.
Arthritis and Rheumatism|July 9, 2003
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacyJacques-Eric Gottenberg, Florence Merle-Vincent, Fabrice Bentaberry, et al.
Arthritis and Rheumatism|January 13, 2011
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label studyJérémie Sellam, Houria Hendel-Chavez, Stéphanie Rouanet, et al.
Rheumatology (Oxford, England)|May 7, 2020
The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission statusCátia Duarte, Eduardo Santos, José A P da Silva, et al.
Annals of the Rheumatic Diseases|May 9, 2020
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritisAndreas Kerschbaumer, Josef S Smolen, Maxime Dougados, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisCécile Gaujoux-Viala, Josef S Smolen, Robert Landewé, et al.
The Journal of Rheumatology|March 11, 2009
Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB studyRene Westhovens, Joel M Kremer, Larry W Moreland, et al.
Clinical and Experimental Rheumatology|October 23, 2013
Fatigue in spondyloarthritis: a marker of disease activity. A cross-sectional study of 266 patientsKarine Chauffier, Simon Paternotte, Vincent Burki, et al.
Pageof 60